La Jolla Institute for Immunology

Beating HIV and COVID-19 may depend on tweaking vaccine molecules

LJI and Scripps Research scientists tackle the problem of antigen valency

Newswise — LA JOLLA—Designing a vaccine starts with finding the right ingredients. Every infectious agent has molecules, called antigens, that the immune system could potentially recognize and attack. So scientists must carefully consider which antigens should go into a vaccine.

Scientists know a lot about how to design vaccines, but there are many diseases that haven't been controlled through vaccination. HIV, for example, mutates quickly and is very good at hiding from the immune system, so it is hard for scientists to figure out which antigens to include in a vaccine.

In a new Immunity study, researchers at La Jolla Institute for Immunology (LJI) show that one way to improve the body's immune response to vaccines is to factor in antigen valency. Valency refers to the number of antibody binding sites on an antigen.

"Differences in valency can impact antibody responses," says Yu Kato, Ph.D., postdoctoral fellow at LJI and first author of the new study.

You can think of antigen valency like the nubbins on Lego pieces. With a higher valency, antibodies have more sites to latch onto. But including a higher antigen valency in a vaccine doesn't mean it works better.

"Different vaccines have vastly different valencies. Diphtheria toxin is a dimer, valency of 2. Hep B vaccine is 100–120," explains Kato. "There is no clear consensus as to how the differing valencies impact B cell responses since these antigens also differ in many other ways."

For the new study, the researchers worked closely with the LJI Microscopy Core and used an advanced imaging technique called two-photon microscopy to visualize the effects of valencies on B cell responses.

The researchers discovered that high-valency antigens can lead the body to make more antibody-producing B cells. It's like the immune system sees the many targets on these antigens and takes a scatter-shot approach at hitting them. In fact, a valency of 60 seems to be enough to boost B cell numbers, and a valency of four might be enough in many cases.

"Valency matters, but you don't need a valency of 1,000 engineered into your vaccine for it to make a difference," says LJI Professor Shane Crotty, Ph.D., who co-led the new study with Professor William Schief, Ph.D., of Scripps Research.

Low-valency antigens do lead to a smaller, more targeted B cell response. These B cells are rarer, but they are more likely to be sharp-shooters. These cells are said to have a "high affinity."

Scientists have known about valency for a long time, but it had been hard to test which antigen valencies would work best in vaccines.

A big problem is that different pathogens don't just differ in valency. They also have different structures, different modes of entering cells, and different strategies for evading the immune system. This means scientists studying the effects of valency are stuck comparing apples to oranges.

"Proteins are really unique, so we had to turn it into an apples-to-apples comparison," says Crotty.

To solve this problem, the researchers teamed up with the Schief lab at Scripps Research. Schief and his colleagues had developed versions of an HIV protein with antigen valencies that ranged from one to 60. These antigens were all based on proteins from HIV, making them superior to engineered antigens used for previous valency studies. The LJI and Scripps Research teams then worked together to test the antigens in mice.

"In collaboration with the Schief lab, we developed a platform that allowed us to display different antigens," says Kato. "This platform was designed in a way that allows us to compare responses in a fair way."

The researchers concluded that while vaccines need a valency of more than one binding site, choosing a valency of four over a valency of 60 doesn't have a big effect on B cell responses.

Valency will still be an important ingredient to consider in vaccine design. For example, because HIV is hard for the immune system to recognize, the B cells that target the virus are very rare. That means high-valency antigens could help boost those rare B cell populations by spurring a more-is-better immune system reaction.

Selecting antigens with the right valency will really depend on the disease scientists are trying to target. "Depending on the type of B cells we need to prime, we need to think about which valency may be best," says Kato.

Scientists may also need to consider valency when designing COVID-19 vaccines. Different labs around the world are testing vaccines that contain antigens with many different valencies. Which will work best? "It's definitely possible to address that question, and COVID researchers are playing with ways to exploit valency effects," Kato says.

“Dr. Kato did a beautiful job elucidating the impact of valency and several other molecular parameters on vaccine responses," adds Schief. "This has been a very rewarding collaboration, and we will certainly be using information from this study in our future vaccine designs for HIV, SARS-CoV-2 and other pathogens.”

The study, titled "Multifaceted effects of antigen 1 valency on B cell response composition  and differentiation in vivo," was supported by the National Institutes of Health (S10OD021831); the National Institute of Allergy and Infectious Diseases (Al100663, UM1 AI144462, AI048240);  the U.S. Department of Defense (award W911NF-18-2-0048); and the Ragon Institute of MGH, MIT, and Harvard.

Additional study authors include Robert K. Abbott, Brian L. Freeman, Sonya Haupt, Bettina Groschel, Murillo Silva, Sergey Menis and Darrell J. Irvine.

DOI: https://doi.org/10.1016/j.immuni.2020.08.001

###

About La Jolla Institute for Immunology

The La Jolla Institute for Immunology is dedicated to understanding the intricacies and power of the immune system so that we may apply that knowledge to promote human health and prevent a wide range of diseases. Since its founding in 1988 as an independent, nonprofit research organization, the Institute has made numerous advances leading toward its goal: life without disease.

 




Filters close

Showing results

110 of 3381
Released: 24-Sep-2020 10:10 AM EDT
Rebound or Permanent Slump? Possible Impacts of US COVID-19 Fiscal Policies
University of Virginia Darden School of Business

Fiscal policy is a powerful tool to combat economic downturns, but the results depend on decreasing inequality, an imperative to the efficacy of fiscal multipliers. As COVID-19 cases rise, new research offers insights into which fiscal policies may bolster the economy — and the other options, which may have long-term ramifications.

access_time Embargo lifts in 2 days
Embargo will expire: 24-Sep-2020 2:00 PM EDT Released to reporters: 24-Sep-2020 9:25 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 24-Sep-2020 2:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 24-Sep-2020 5:05 AM EDT
Many Americans continue to maintain unhealthy lifestyle habits during COVID-19; overeating, alcohol drinking and marijuana use increase while exercise declines, reports USC Center for the Digital Future
USC Annenberg School for Communication and Journalism

After more than six months of living in a pandemic, large percentages of Americans continue to indulge in unhealthy lifestyle habits, including overeating and increased use of alcohol and marijuana — all while many are exercising less, according to a study of the cultural impact of COVID-19 conducted by the USC Center for the Digital Future (CDF).

Newswise: Houston Methodist COVID-19 study shows rapid spread and potential for mutant viruses
Released: 23-Sep-2020 4:55 PM EDT
Houston Methodist COVID-19 study shows rapid spread and potential for mutant viruses
Houston Methodist

Molecular analysis of COVID-19’s powerful second wave in Houston shows a mutated virus strain linked to higher transmission and infection rates than the coronavirus strains that caused Houston’s first wave. Gene sequencing results from 5,085 COVID-positive patients tested at Houston Methodist since early March show a virus capable of adapting, surviving and thriving – making it more important than ever for physician scientists to understand its evolution as they work to discover effective vaccines and therapies.

Newswise: Likely molecular mechanisms of SARS-CoV-2 pathogenesis are revealed by network biology
Released: 23-Sep-2020 4:00 PM EDT
Likely molecular mechanisms of SARS-CoV-2 pathogenesis are revealed by network biology
University of Alabama at Birmingham

Researchers combined a lung-epithelial cell host interactome with a SARS-CoV-2 interactome. Network biology analysis of this human/SARS-CoV-2 interactome revealed potential molecular mechanisms of pathogenesis for SARS-CoV-2, the virus responsible for the COVID-19 pandemic.

Newswise: Statins Reduce COVID-19 Severity, Likely by Removing Cholesterol That Virus Uses to Infect
Released: 23-Sep-2020 3:45 PM EDT
Statins Reduce COVID-19 Severity, Likely by Removing Cholesterol That Virus Uses to Infect
University of California San Diego Health

Analyzing anonymized patient medical records, UC San Diego researchers discovered that cholesterol-lowering statins reduced risk of severe COVID-19 infection, while lab experiments uncovered a cellular mechanism that helps explain why.

Newswise: Flu Season Returns As The COVID-19 Pandemic Continues
Released: 23-Sep-2020 2:00 PM EDT
Flu Season Returns As The COVID-19 Pandemic Continues
Johns Hopkins Medicine

As the COVID-19 pandemic continues with no end in sight, the annual flu season emerges once again. Cases of the flu have already begun to surface around the nation, and there are some reports of co-infection with COVID-19. Johns Hopkins Medicine experts say now is the time to take action to fight against the flu. Doctors recommend that everyone age 6 months and older get the flu vaccine each year to prevent infection from the virus or reduce the severity of the illness.

Released: 23-Sep-2020 1:45 PM EDT
Mathematics: Modelling the timings of a COVID-19 second wave in Europe
Scientific Reports

How a second wave of COVID-19 infections may evolve across Europe over the next few months, using data on infection rates and travel within and between European countries, is modelled in a Scientific Reports paper.

Released: 23-Sep-2020 1:20 PM EDT
Study: Death counts fail to capture full mortality effects of COVID-19
University of South Florida

More than 200,000 people in the U.S. have died from COVID-19.

Released: 23-Sep-2020 1:10 PM EDT
Q&A: What’s in store for retailers during a pandemic holiday season?
Michigan State University

The 2020 holiday season, much like the majority of the year, will be like none other before. But what does this mean for retailers? Simone Peinkofer, assistant professor of supply chain management at Michigan State University’s Eli Broad College of Business, discusses what holiday consumerism may look like for consumers and retailers alike.


Showing results

110 of 3381

close
0.89542